Figure 4From: Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early resultsPR-25. EORTC QLQ-PR-25 changes (mean). a: urinary symptoms, b: bowel symptoms, c: sexual function.Back to article page